May 6, 2019Open Access

Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma

Key Points

Key points are not available for this paper at this time.

Abstract

ctDNA assessment for early risk stratification, therapy monitoring, and early relapse detection in bladder cancer is feasible and provides a basis for clinical studies that evaluate early therapeutic interventions.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Cite this study

Christensen et al. (Mon,) studied this question.

www.synapsesocial.com/papers/69d8b0925c3030ff03d1a553 — DOI: https://doi.org/10.1200/jco.18.02052

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis· 2017 · 173 citations
Postoperative Nomogram Predicting Risk of Recurrence After Radical Cystectomy for Bladder Cancer· 2006 · 459 citations
Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer· 2014 · 296 citations
Limits of Tumor Detectability in Nuclear Medicine and PET· 2012 · 99 citations

Authors

Emil Christensen

Karin Birkenkamp‐Demtröder

Himanshu Sethi

Journals

Journal of Clinical Oncology

Actions

Institutions

Aarhus University

Aarhus University Hospital

Natera (United States)

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion